Aim: Our objective was to identify a more potent curcumin derivative with specific activity against Mycobacterium tuberculosis.
Materials & Methods: A total of 21 curcumin derivatives were synthesized and detailed bio-evaluation was carried out including determination of static/cidality, synergy with front-line antituberculosis drugs and determination of efficacy in the murine model of M. tuberculosis infection.
Results: We identified CPMD-6d dihydrochloride exhibiting concentration-dependent bactericidal activity against M. tuberculosis (MIC 2 μg/ml), even against drug-resistant strains. In addition, it synergizes with front-line antituberculosis drugs as well as significantly reduces bacterial load in mice lungs and spleen at 25 mg/kg as compared with ethambutol at 100 mg/kg.
Conclusion: Taken together, CPMD-6d dihydrochloride exhibits all properties to be positioned as a novel molecule of interest for treatment of tuberculosis. Graphical abstract: [Formula: see text].
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fmb-2017-0054 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis.
Antimicrob Agents Chemother
November 2024
Department of Microbiology, Immunology and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
Article Synopsis
- Scientists created new medicines called spectinamides to help treat tuberculosis (TB) more effectively.
- One of these, named MBX-4888A, works well with other TB drugs like rifampin and pyrazinamide in mice.
- The research showed that using MBX-4888A can help shorten the treatment time for TB and seems to be safe for long-term use in mice.
Immunoinhibitory effects of anti-tuberculosis therapy induce the host vulnerability to tuberculosis recurrence.
Microbiol Spectr
July 2024
Immunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
The host immune responses play a pivotal role in the establishment of long-term memory responses, which effectively aids in infection clearance. However, the prevailing anti-tuberculosis therapy, while aiming to combat tuberculosis (TB), also debilitates innate and adaptive immune components of the host. In this study, we explored how the front-line anti-TB drugs impact the host immune cells by modulating multiple signaling pathways and subsequently leading to disease relapse.
View Article and Find Full Text PDFArticle Synopsis
- Spectinamides are new medicines that help fight TB (tuberculosis), modified to work better in the body.
- In studies with mice, one type called MBX-4888A showed it could improve treatment when used with other TB drugs.
- This research tested how well it works in different mouse models, showing it's safe and might help cure TB faster.
[6]-Gingerol exhibits potent anti-mycobacterial and immunomodulatory activity against tuberculosis.
Int Immunopharmacol
October 2020
International Centre for Genetic Engineering and Biotechnology, New Delhi, India. Electronic address:
The currently available anti-tuberculosis treatment (ATT) comprises exclusively of anti-bacterial drugs, is very lengthy, has adverse side effects on the host and leads to the generation of drug-resistant variants. Therefore, a combination therapy directed against the pathogen and the host is required to counter tuberculosis (TB). Here we demonstrate that [6]-Gingerol, one of the most potent and pharmacologically active ingredients of ginger restricted mycobacterial growth inside the lungs, spleen and liver of mice infected with Mycobacterium tuberculosis (Mtb).
View Article and Find Full Text PDFDrug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development.
IUBMB Life
September 2018
Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, South Africa.
Anti-tuberculosis (TB) drugs possess diverse abilities to penetrate the different host tissues and cell types in which infecting Mycobacterium tuberculosis bacilli are located during active disease. This is important since there is increasing evidence that the respective "lesion-penetrating" properties of the front-line TB drugs appear to correlate well with their specific activity in standard combination therapy. In turn, these observations suggest that rational efforts to discover novel treatment-shortening drugs and drug combinations should incorporate knowledge about the comparative abilities of both existing and experimental anti-TB agents to access bacilli in defined physiological states at different sites of infection, as well as avoid elimination by efflux or inactivation by host or bacterial metabolism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!